2025-11-10
Recently, in a laboratory at China Pharmaceutical City in Taizhou, Jiangsu Province, recombinant feline omega-interferon is undergoing pre-market stability studies, with the compilation and analysis of key data now in the final stages. Researchers are holding their breath, as this small pharmaceutical product—alongside the “Miaobeihu” feline trivalent inactivated vaccine, which was just approved here two months ago—represents not only a breakthrough from zero to one in China’s pet biopharmaceutical sector, but also signals the emergence of a formidable “Chinese force” in an industry long dominated by international giants.
Learn more